https://www.selleckchem.com/products/ABT-888.html
The difference the in O/E ratio among the groups was statistically significant (P less then .001). The average episode target price for cohorts A, B, and C was $66,149, $63,483, and $63,937, respectively. Despite the high cost of pomalidomide and lenalidomide, there was no significant difference in the average episode target prices of the cohorts. Conclusion The O/E ratio and target prices of the cohorts demonstrate a lack of adequate adjustment to the OCM target price for episodes in which pomalidomide and lenalidomide were used to tre
Gefällt mir
Kommentar
Teilen
